A Comprehensive Supply Chain for Core Intermediates in Diabetes Treatment
End-to-end supply chain for anti-diabetic intermediates. Covering DPP-4, SGLT-2 inhibitors & GPR40 agonists. Stable, compliant, scalable.
March 6, 2026
5-Bromo-4-fluoro-1-methyl-1H-indazole
5-Bromo-4-fluoro-1-methylindazole; 1H-Indazole, 5-bromo-4-fluoro-1-methyl-; 5-Bromo-4-fluoro-1-m; Orforglipron Intermediates
CAS: 1784678-61-0
Chemical Formula: C₈H₆BrFN₂
Molecular Weight: 229.05
Availability: R&D; Commercialization
5-bromo-4-fluoro-1-methyl-1H-indazole
⬤ CAS No.1784678-61-0
⬤ Our Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| Product Name | 5-bromo-4-fluoro-1-methyl-1H-indazole |
| CAS.No | 1784678-61-0 |
| Molecular Formula | C₈H₆BrFN₂ |
| Molecular Weight | 229.05 |
| Related Categories | Orforglipron Intermediates |
| Appearance | solid |
| Boiling Point | 293.4±20.0 °C(Predicted) |
| Density | 1.70±0.1 g/cm³ (Predicted) |
| Acidity coefficient（pKa） | -0.38±0.30 (Predicted) |
| Flash Point | 131.3±21.8 °C (Predicted) |
| Chemical Structure | The compound is a halogenated indazole derivative, and its structural characteristics are that the benzene ring is fused with the pyrazole ring, the bromine and fluorine atoms are connected at the 5-position and 4-position respectively, and the methyl group is connected at the 1-position. |
| Dangerous goods signs | GHS07 Warning |
| Hazard Labeling | H302 (Note: Harmful if swallowed) |
| Application | 5-Bromo-4-fluoro-1-methyl-1H-indazole is an important intermediate in the synthesis of potential drug candidates in various therapeutic areas, including cancer, neurodegenerative diseases, and infectious diseases. |
Customer Reviews
Real customer feedback
Michael Carter
Reliable Global Partner
“Tianming Pharmaceutical has redefined reliability for us. Their ability to deliver high-potency APIs and intermediates under tight deadlines—is unmatched. The team’s transparency in documentation and proactive updates make them a stress-free partner. A true backbone for our operations!”
March 18, 2024
Dr. Sofia Alvarez
Outstanding Technical Guidance
“Few suppliers align so perfectly with EU GMP requirements. Tianming’s commitment to audit-ready quality systems, batch traceability, and purity consistency has streamlined our production processes. Their diligence eliminates regulatory risks—a rare advantage in today’s market.”
February 15, 2024
Rajesh Kapoor
Beyond Supplier, A Solutions Partner
“Tianming’s technical team doesn’t just deliver materials—they solve problems. When we faced stability challenges with a niche compound, their scientists proposed a tailored purity adjustment that saved our project timeline. Their agility transforms obstacles into opportunities.”
June 15, 2024
Emily Zhang
Strategic Growth Ally
“Over 5+ years, Tianming has consistently adapted to our evolving needs—whether scaling volumes or supporting custom synthesis projects. Their ethical pricing models and long-term vision make them more than a vendor; they’re integral to our competitive edge.”
April 27, 2024
What's News
Latest news at Tianming
CDMO vs. Direct Manufacturer: Which Model Fits Your API Strategy?
Drawing from on-the-ground experience in China’s top pharma clusters, this guide cuts through the jargon to reveal when to partner for complex innovation and when to buy from the workhorses of mature production.
March 3, 2026
Case Study: Improving Yield & Purity Through Route Optimization
This case study, based on publicly available academic literature and patents, focuses on the application of synthetic route optimization in improving the yield and purity of Active Pharmaceutical Ingredients (APIs).
February 27, 2026
Still Have Questions？
If you still have questions or need more information, our team is here to help. Please don’t hesitate to contact us for personalized assistance.